Objectives: To asses risk factors for a first thrombotic event in antiphospholipid antibody
(aPL) positive carriers and evaluate the efficacy of prophylactic treatments. Methods …

Antiphospholipid syndrome (APS) is a thromboinflammatory syndrome characterized by
thrombotic, microvascular, obstetric, or non-thrombotic events in the setting of persistent …

Objective. Most clinicians use the 2006 Sydney classification criteria to evaluate patients
suspected of having antiphospholipid syndrome (APS). Although sensitive and specific for …

The presence of antiphospholipid antibodies (aPL) combined with venous or arterial
thrombosis, and/or obstetric complications defines the antiphospholipid syndrome (APS) …

Objective The primary objective of this study was to evaluate the safety of rituximab in
antiphospholipid antibody (aPL)–positive patients with non‐criteria manifestations of …

Objective It has been suggested that only antibodies against domain 1 (D1) of β2‐
glycoprotein I (β2GPI) are pathogenic and diagnostic. The role of antibodies against other …

Objectives aPL are frequently present in SLE. In a well characterized SLE cohort we aimed
at investigating the prevalence of aPL and assessing their analytical performance and …

Background Specific anti-phospholipids antibodies (aPLs) are used as classification criteria
of the antiphospholipid syndrome (APS). These aPLs, although essential for diagnosis, do …

Objective The present study was undertaken to longitudinally evaluate titers of antibodies
against β2‐glycoprotein I (anti‐β2GPI) and domain 1 (anti‐D1), to identify predictors of …

The Antiphospholipid syndrome (APS), formerly known as Anticardiolipin or Hughes
syndrome, is a systemic autoimmune disorder characterized by obstetrical complications …